

## Arzneimitteltherapie bei Niereninsuffizienz

### Les médicaments dans l'insuffisance rénale

#### Literatur / Références

- [1] Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J, Seger DL, et al. Guided medication dosing for inpatients with renal insufficiency. *JAMA* 2001;286(22):2839–44.
- [2] Bertsche T, Fleischer M, Pfaff J, Encke J, Czock D, Haefeli WE. Pro-active provision of drug information as a technique to address overdosing in intensive-care patients with renal insufficiency. *European journal of clinical pharmacology* 2009;65(8):823–9.
- [3] Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. *Kidney international* 2012;81(9):819–25.
- [4] Ng BL, Anpalahan M. Management of chronic kidney disease in the elderly. *Internal medicine journal* 2011;41(11):761–8.
- [5] Vilay AM, Churchwell MD, Mueller BA. Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury. *Critical care (London, England)* 2008;12(6):235.
- [6] Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. *Pharmacology & therapeutics* 2006;109(1–2):1–11.
- [7] Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. *Expert opinion on drug metabolism & toxicology* 2008;4(8):1065–74.
- [8] Bianchetti G, Graziani G, Brancaccio D, Morganti A, Leonetti G, Manfrin M, et al. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. *Clinical pharmacokinetics* 1976;1(5):373–84.
- [9] Brater DC. Drug dosing in patients with impaired renal function. *Clinical pharmacology and therapeutics* 2009;86(5):483–9.
- [10] Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16(1):31–41.
- [11] Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Annals of internal medicine* 1999;130(6):461–70.
- [12] Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Annals of internal medicine* 2009;150(9):604–12.
- [13] Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. *Jama* 2012;307(18):1941–51.
- [14] Wang X, Lewis J, Appel L, Cheek D, Contreras G, Faulkner M, et al. Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. *J Am Soc Nephrol* 2006;17(10):2900–9.
- [15] Stevens LA, Padala S, Levey AS. Advances in glomerular filtration rate-estimating equations. *Current opinion in nephrology and hypertension* 2010;19(3):298–307.
- [16] McKenzie C. Antibiotic dosing in critical illness. *The Journal of antimicrobial chemotherapy* 2011;66 Suppl 2(ii25–31).
- [17] Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? *Archives of internal medicine* 2000;160(5):685–93.
- [18] Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. *Annals of internal medicine* 2001;135(2):73–87.
- [19] Bourquin V, Petignat PA, Besson M, Piguat V. [Analgesia and renal insufficiency]. *Revue medicale suisse* 2008;4(175):2218–20, 22–3.
- [20] Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. *Clinical pharmacokinetics* 1996;31(6):410–22.
- [21] Schmid P, Fischer AG, Wuillemin WA. Low-molecular-weight heparin in patients with renal insufficiency. *Swiss medical weekly* 2009;139(31–32):438–52.
- [22] Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2 Suppl):e24S–43S.
- [23] Schmid P, Brodmann D, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. *J Thromb Haemost* 2009;7(4):552–8.
- [24] Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. *J Thromb Haemost* 2009;7(10):1629–32.

- [25] Shprecher AR, Cheng-Lai A, Madsen EM, Cohen HW, Sinnott MJ, Wong ST, et al. Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. *Pharmacotherapy* 2005;25(6):817–22.
- [26] Mismetti P, Samama CM, Rosencher N, Vielpeau C, Nguyen P, Deygas B, et al. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study. *Thrombosis and haemostasis* 2012;107(6):1151–60.
- [27] Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? *Clinical cardiology* 2012;33(10):604–8.
- [28] Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. *British journal of clinical pharmacology* 2012;73(3):447–54.
- [29] Wattenwyl Tv, Sandoz P. Akute interstitielle Nephritiden. *Schweizerisches Medizinisches Forum* 2003;38(891–7).
- [30] Olyaei AJ, Bennett WM. Drug dosing in the elderly patients with chronic kidney disease. *Clinics in geriatric medicine* 2009;25(3):459–527.
- [31] Brunton LL, editor. *Goodman & Gilman's The Pharmacological Basis of THERAPEUTICS*. 12 ed: McGraw-Hill; 2011.
- [32] Lovric S, Kielstein JT, Kayser D, Brocker V, Becker JU, Hiss M, et al. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series. *Nephrol Dial Transplant* 2011;26(9):3032–8.
- [33] Perazella MA. Renal vulnerability to drug toxicity. *Clin J Am Soc Nephrol* 2009;4(7):1275–83.
- [34] Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. *Kidney international* 2008;74(11):1385–93.
- [35] Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. *The New England journal of medicine* 2003;349(17):1676–9; discussion -9.
- [36] Wiedermann CJ, Dunzendorfer S, Gaioni LU, Zaraca F, Joannidis M. Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. *Critical care (London, England)* 2010;14(5):R191.
- [37] Perazella MA. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. *Kidney international* 2010;78(11):1060–3.
- [38] Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. *Seminars in nephrology* 2011;30(6):570–81.